New Patent Underscores Intellect's Leadership in Immunotherapy for
NEW YORK, Sept. 19 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, announced today that European Patent No. 1237930 covering chimeric peptide vaccines has been validated in nineteen European countries. The nine month opposition period for the patent expired on August 8, 2007. The patent also has been granted in several other countries outside of Europe. Intellect Neurosciences is the exclusive assignee of the patent, which relates to the Company's RECALL-VAX(TM) technology.
"The validation of our patent in Europe strengthens our competitive advantage in a therapeutic area that is a front runner in the attack against Alzheimer's disease," commented Dr. Daniel Chain, Intellect's Chairman and Chief Executive Officer. "We are excited about this promising technology that possesses a unique combination of safety features, which potentially enables it to be used to treat patients suffering from Alzheimer's disease and also to prevent or delay the onset of this devastating disease."
"There are multiple challenges in developing a means to safely immunize
elderly individuals and avoid the failures encountered in previous clinical
trials sponsored by major pharmaceutical companies," commented Professor
Benjamin Chain, at the Department of Immunology and Molecular Pathology,
Windeyer Institute of Medical Sciences, University College London.
Professor Chain is the inventor of RECALL-VAX(TM) and is a member of
Intellect's Scientific Advisory Board. Professor Chain added: "The major
challenges are the need to: mount a robust immune response when the immune
system has become senescent as the result of age; avoid autoimmune
|SOURCE Intellect Neurosciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved